IP Verse

Competitive analysis in Form Specific Drugs industry

Latest patents granted in the Form Specific Drugs industry

Patent:
EP2571517
Grant Date:
Oct 16, 2024
Title:
Long - Acting Formulations Of Insulins
Applicant:
SANOFI
Patent:
EP2819699
Grant Date:
Oct 16, 2024
Title:
Controlled Release Compositions And Their Methods Of Use
Applicant:
BAYER NEW ZEALAND LIMITED
Patent:
EP3506884
Grant Date:
Sep 25, 2024
Title:
Drug Delivery Compositions And Uses Thereof
Applicant:
DANA-FARBER CANCER INSTITUTE, INC.
Patent:
EP3236954
Grant Date:
Sep 4, 2024
Title:
Enteric Film Coating Compositions, Method Of Coating, And Coated Forms
Applicant:
DUPONT NUTRITION USA, INC.
Patent:
EP2736487
Grant Date:
Aug 28, 2024
Title:
New (Trimethoxyphenylamino)Pyrimidinyl Formulations
Applicant:
RIGEL PHARMACEUTICALS, INC.
Patent:
EP3236939
Grant Date:
Aug 28, 2024
Title:
Botulinum Toxin Prefilled Container
Applicant:
MERZ PHARMA GMBH & CO. KGAA
Patent:
EP3076983
Grant Date:
Aug 14, 2024
Title:
Ionic Aqueous Compositions
Applicant:
GEROLYMATOS INTERNATIONAL S.A.
Patent:
EP2687103
Grant Date:
Jul 24, 2024
Title:
Aqueous Transparent Oil-In-Water Emulsion Comprising An Emulsified Carotenoid
Applicant:
BASF SE
Patent:
EP3206987
Grant Date:
Jul 24, 2024
Title:
Nanoparticles For Photodynamic Therapy, X-Ray Induced Photodynamic Therapy, Radiotherapy, Chemotherapy, Immunotherapy, And Any Combination Thereof
Applicant:
THE UNIVERSITY OF CHICAGO
Patent:
EP2104490
Grant Date:
Jun 26, 2024
Title:
Micronised Particles Of Low-Dosage Strength Active Agents For Powder Formulations For Inhalation
Applicant:
CHIESI FARMACEUTICI S.P.A.

Top patents facing oppositions in Form Specific Drugs industry

Patent:
EP2425824
Grant Date:
May 10, 2017
Title:
Pharmaceutical Preparation Containing Oxycodone And Naloxone
Applicant:
MUNDIPHARMA PHARMACEUTICALS S.L.
Oppositions:
286
Patent:
EP2425821
Grant Date:
May 10, 2017
Title:
Pharmaceutical Preparation Containing Oxycodone And Naloxone
Applicant:
MUNDIPHARMA OY
Oppositions:
286
Patent:
EP2791160
Grant Date:
Mar 2, 2022
Title:
Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions
Applicant:
MODERNATX, INC.
Oppositions:
80
Patent:
EP3725778
Grant Date:
Aug 18, 2021
Title:
Formulations Of Enzalutamide
Applicant:
ASTELLAS PHARMA INC.
Oppositions:
66
Patent:
EP3257500
Grant Date:
Oct 16, 2019
Title:
Apixaban Formulations
Applicant:
BRISTOL-MYERS SQUIBB HOLDINGS IRELAND
Oppositions:
60
Patent:
EP3395339
Grant Date:
Dec 11, 2019
Title:
Rapid Dissolution Formulation Of A Cinacalcet Hcl
Applicant:
AMGEN INC.
Oppositions:
44
Patent:
EP3260117
Grant Date:
Nov 27, 2019
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Applicant:
AMGEN, INC
Oppositions:
40
Patent:
EP2817000
Grant Date:
Aug 4, 2021
Title:
Oral Pharmaceutical Compositions Of Dabigatran Etexilate
Applicant:
LABORATORIOS DEL. DR. ESTEVE, S.A.
Oppositions:
36
Patent:
EP3017811
Grant Date:
Dec 5, 2018
Title:
Apixaban Formulations
Applicant:
PFIZER INC.
Oppositions:
36
Patent:
EP3246021
Grant Date:
Nov 13, 2019
Title:
Apixaban Formulations
Applicant:
PFIZER INC.
Oppositions:
36

Top companies filing oppositions in Form Specific Drugs industry

Company:
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Total oppositions filed:
81
Company:
SANDOZ AG
Total oppositions filed:
79
Company:
STADA ARZNEIMITTEL AG
Total oppositions filed:
65
Company:
TEVA PHARMACEUTICAL INDUSTRIES LTD
Total oppositions filed:
52
Company:
GENERICS [UK] LIMITED
Total oppositions filed:
47
Company:
GENERICS (U.K.) LIMITED
Total oppositions filed:
46
Company:
HEXAL AG
Total oppositions filed:
35
Company:
HGF LIMITED
Total oppositions filed:
35
Company:
MAIWALD GMBH
Total oppositions filed:
32
Company:
KRAUS & LEDERER PARTGMBB
Total oppositions filed:
30

Top companies facing oppositions in Form Specific Drugs industry

Company:
NOVARTIS AG
Total facing oppositions:
176
Company:
AMGEN INC.
Total facing oppositions:
97
Company:
PFIZER INC.
Total facing oppositions:
87
Company:
EURO-CELTIQUE S.A.
Total facing oppositions:
65
Company:
AMGEN, INC
Total facing oppositions:
60
Company:
NOVO NORDISK A/S
Total facing oppositions:
54
Company:
CELGENE CORPORATION
Total facing oppositions:
53
Company:
BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY
Total facing oppositions:
52
Company:
BRISTOL-MYERS SQUIBB HOLDINGS IRELAND
Total facing oppositions:
52
Company:
GLAXOSMITHKLINE BIOLOGICALS SA
Total facing oppositions:
50

Need more information?

Feel free to send us a message here and we will get back to you